Diabetologia 2024;67:120622
Continued research will be required to examine the long-term safety implications of DPP-4 inhibitors, as well as to discover off-target and congeneric clinical applications in order to fully realize these advantages
The difference is that it has no side effects
Injection site reactions are also documented across this class, and the FDA has separately described an adverse event report involving a product falsely labelled as compounded tirzepatide, with symptoms including redness, injection site swelling, pain and a red lump
What are the possible side effects of SYMLIN
RYBELSUS - Tabletas Sustancia(s): Semaglutida Presentaciones: 1 Caja, 10 Tabletas, 3 mg 1 Caja, 30 Tabletas, 3 mg 1 Caja, 60 Tabletas, 3 mg 1 Caja, 90 Tabletas, 3 mg 1 Caja, 10 Tabletas, 7 mg 1 Caja, 30 Tabletas, 7 mg 1 Caja, 60 Tabletas, 7 mg 1 Caja, 90 Tabletas, 7 mg 1 Caja, 10 Tabletas, 14 mg 1 Caja, 30 Tabletas, 14 mg 1 Caja, 60 Tabletas, 14 mg 1 Caja, 90 Tabletas, 14 mg FORMA FARMACUTICA Y FORMULACIN: Cada TABLETA contiene: Semaglutida* 3 mg, 7 mg, 14 mg Excipiente cbp 1 tableta *Anlogo humano del pptido similar al glucagn tipo 1 (GLP-1) de origen ADN recombinante expresado en Saccharomyces cerevisiae Excipiente con efecto conocido: Cada tableta, independientemente de la dosis de semaglutida, contiene 23 mg de sodio INDICACIONES TERAPUTICAS: RYBELSUS est indicado para el tratamiento de adultos con diabetes mellitus tipo 2 que no han sido controlados adecuadamente, para mejorar el control glucmico, como un complemento de la dieta y el ejercicio: En monoterapia cuando la metformina se considera inapropiada debido a intolerancia o a las contraindicaciones
